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Abstract
Background: Recently developed measures such as I2 and H allow the evaluation of the impact of
heterogeneity in conventional meta-analyses. There has been no examination of the development
of heterogeneity in the context of a cumulative meta-analysis.
Methods: Cumulative meta-analyses of five smoking cessation interventions (clonidine, nicotine
replacement therapy using gum and patch, physician advice and acupuncture) were used to
calculate I2 and H. These values were plotted by year of publication, control event rate and sample
size to trace the development of heterogeneity over these covariates.
Results:  The cumulative evaluation of heterogeneity varied according to the measure of
heterogeneity used and the basis of cumulation. Plots produced from the calculations revealed
areas of heterogeneity useful in the consideration of potential sources for further study.
Conclusion: The examination of heterogeneity in conjunction with summary effect estimates in a
cumulative meta-analysis offered valuable insight into the evolution of variation. Such information
is not available in the context of conventional meta-analysis and has the potential to lead to the
development of a richer picture of the effectiveness of interventions.
Background
As predicted by Mulrow [1,2] (among others), reports of
meta-analyses – the suite of statistical techniques used to
arrive at pooled estimates of effects across a series of stud-
ies (often but not always) during the course of a system-
atic review – have ballooned in parallel with the rapid and
sustained pace at which information becomes available
about the efficacy of interventions. Often, meta-analyses
are conducted after a collection of studies have been iden-
tified; statistical pooling occurs at one point in time. The
sequential pooling of the effect estimate in a "cumulative"
manner as studies are published or according to other spe-
cific variables of interest (study quality or control event
rate, for instance) were described and developed by Lau
and colleagues [3-5]. These developments have focused
on describing the evolution of the point estimate and its
confidence intervals.
Conventional meta-analyses are usually reported in con-
junction with a test for heterogeneity. A popular statistic,
Cochran's  Q, is the sum of the squared differences
between each study's effect estimate and the overall effect
estimate, weighted for the information provided by the
particular study [6,7]. Traditionally, Q has been used as a
formal test of homogeneity as, under the null hypothesis,
it follows a chi-squared distribution with degrees of free-
dom equal to the total number of studies less one. In spite
of its problems [8], Q  is widely used as a means of
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determining whether statistically significant heterogeneity
is present.
Moving forward from this binary consideration, Higgins
and colleagues [9,10] proposed measures to quantify the
impact (as opposed to the extent) of heterogeneity in
meta-analyses. Two measures have particular intuitive
appeal. H2, the ratio of Q to its degrees of freedom, may
be roughly interpreted as the ratio of confidence interval
widths for single summary estimates from random effect
and fixed effect meta-analyses. I2 describes the amount of
heterogeneity among studies relative to the total variabil-
ity among the effect estimates.
Cumulative meta-analytic techniques have revealed how
estimates of effect evolve across time. How is the temporal
progress of heterogeneity characterised? We are not aware
of studies that have examined measures of heterogeneity
in the context of a cumulative meta-analysis. To this end,
we were interested in describing H2 and I2 in sequentially
pooled effect estimates when cumulative meta-analysis is
performed.
Methods
Measures of heterogeneity
Higgins and colleagues [9] derived three candidate meas-
ures of the extent of heterogeneity in a meta-analysis, two
of which are considered in this paper. The measures were
created to meet three specific criteria. First, the measure
was to increase as the variance in the underlying treatment
effects increases. Second, the measure was not to be
affected by the scale of measurement or the type of out-
come being considered. Lastly, the measure was not to
depend on the number of studies.
H2 represents the proportional surfeit of Q relative to its
degrees of freedom (or the number of studies, k, less one),
Given that E [Q] = k - 1 in the absence of heterogeneity, a
value of 1 for H2 indicates an absence of heterogeneity.
Higgins and colleagues make several recommendations
about the use of H2, including the use of the square root
of H2 (or H) in the same way that discussions about the
standard deviation are more familiar to clinicians than are
discussions about the variance; the use of a test-based
standard error for the natural logarithm of H
leading to the calculation of the 100(1-2α)% confidence
interval (i.e., the estimated range of values which has a
probability 100(1-2α)% of including the unknown popu-
lation parameter) for H as
and taking the maximum out of H and 1 [9].
First examined by Takkouche, Cadarso-Suarez and
Spiegelman [11] in the context of meta-analyses of obser-
vational studies, I2 represents the proportion of the total
variability (i.e., the sum of between-study variance τ2 and
residual variability arising from sampling errors averaged
across all studies σ2) that is explained by the variability in
the underlying treatment effects
In the absence of heterogeneity, I2 = 1. The two measures
are related through
and leads to the calculation of confidence intervals for I2
using equations 2 and 3.
Motivating systematic reviews
We chose four systematic reviews of randomised control-
led trials relating to different interventions designed to
promote smoking cessation: acupuncture [12], clonidine
[13], nicotine replacement therapy (reported separately
for gum and patch) [14], and physician advice [15]. The
reviews were published in the third issue of 2003 of the
Cochrane Database of Systematic Reviews, although the
reviews themselves were last updated in 2001 [13,15] or
2002 [12,14]. As the focus of the present paper is hetero-
geneity as a methodological phenomenon, we invite read-
ers to examine the latest version of the Cochrane Library
for a current exposition of the effectiveness of these
interventions.
Clonidine: No heterogeneity in final analysis, presence of 
statistically significant effect
Clonidine, traditionally used to lower blood pressure, has
been used as a therapy for smoking cessation as it may
reduce symptoms of withdrawal via its action on the cen-
tral nervous system. The meta-analysis performed by
Gourlay and colleagues analysed the effectiveness of clo-
nidine therapy (oral or transdermal) versus placebo in
smoking cessation [13]. While only one of the six studies
included in the meta-analysis showed that clonidine was
statistically significantly more effective than placebo, the
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resulting meta-analysis showed that clonidine was more
effective overall. The authors concluded that it was rea-
sonable to consider clonidine as second-line therapy for
smoking cessation [13]. The value of I2 in a meta-analysis
containing all studies is zero.
Nicotine replacement: Minimal heterogeneity in final 
analysis, presence of statistically significant effect
Nicotine replacement therapy has been used to aid in
smoking cessation by replacing nicotine from cigarettes,
thereby reducing withdrawal symptoms. Different forms
of nicotine replacement therapies exist and these include
nicotine gum, transdermal patches, nasal spray, inhalers
and tablets. The results of the meta-analysis performed by
Silagy and colleagues indicated that all of the commer-
cially available forms of nicotine replacement therapy
were effective in promoting smoking cessation and that
nicotine replacement was more effective than placebo in
achieving smoking cessation independent of therapy
duration and the level of additional support and advice
[14]. In this paper, we focus on the effects of nicotine
replacement in gum and patch form. The value of I2 in a
meta-analysis containing all studies is 19.41% for gum
and 28.57% for patch.
Physician advice: Moderate heterogeneity in final analysis, 
presence of statistically significant effect
Physicians may play an important role in facilitating
smoking cessation by providing advice (ranging from
brief to intensive) to patients on how their health can
improve by quitting. Silagy and Stead [15] examined the
effectiveness of advice from physicians in promoting
smoking cessation. Results indicated that brief advice was
more effective than no advice on smoking cessation. The
value of I2 in a meta-analysis containing all studies is
35.51%.
Acupuncture: Moderate heterogeneity in final analysis, no 
statistically significant effect
Treatment with acupuncture and related therapies has
been used to aid patients cease dependence on addictive
drugs by reducing withdrawal symptoms. White and col-
leagues performed a meta-analysis to assess the effective-
ness of acupuncture, acupressure, laser therapy and
electrostimulation on smoking cessation compared with
sham treatment, other interventions or no intervention
[12]. The authors concluded that the evidence did not sug-
gest that any of these techniques were more effective than
placebo for smoking cessation. The value of I2 in a meta-
analysis containing all studies is 49.98%.
Cumulative meta-analysis
Using each of the five smoking cessation interventions, we
conducted a cumulative meta-analysis based on repeated
pooling of individual studies according to publication
year, control group event rate, and study size. The fixed-
effects model described by Mantel and Haenszel [16] was
used to arrive at summary estimates and confidence inter-
vals for the odds ratio (OR) of the primary intervention in
the treatment group versus the control group. Measures of
heterogeneity were calculated at each pooling event and
plotted alongside the summary statistic in a forest plot. All
calculations were performed on Stata 8.2 SE (StataCorp
Inc, College Station, Texas, USA).
Results
Figure 1 describes the evolution of the OR (first row), Q
(second row) and I2 (third row) for each of the five inter-
ventions. We performed cumulative meta-analyses in the
order in which studies were published. As expected, Q is
non-decreasing over the entire period. Moreover, the aver-
age changes in Q are equally inconsistently reflected in the
changes in the OR. For instance, the OR for nicotine
replacement using patches changes only by 12% from
1996 to 2000 while Q changes by more than 130%. Note
the difficulty of comparing Q across studies because of the
different ranges as exemplified by the varying ordinates.
The utility of I2 is immediately apparent. First, the use of
standard limits from 0 to 1 allows comparisons to be
made between different meta-analysis. Second, the abso-
lute level of I2 may be interpreted in a meaningful way. For
instance, we see that between-study variance (τ2) played a
minimal role in comparison to within-study variance (σ2)
prior to 1993 for clonidine while essentially disappearing
after this time. In contrast, the results for physician advice
and acupuncture showed that τ2 was proportionally large
in earlier cumulations. While there was a decrease in the
overall level over time, the absolute amounts remained
above 35%.
Third, changes in I2 correlate well with changes in the OR,
but plateauing of the OR does not necessarily mean a pla-
teauing of I2. The dips and rises in the OR are reflected in
the rise or fall of I2. This can be seen quite clearly in the
early and middle periods in the cumulations of both gum
and patch. The slight perturbations in the OR are magni-
fied in trends and absolute levels of I2. However, a steady
level of the OR does not necessarily mean that the I2 value
stabilises, too. This is seen in the different behaviour of I2
during the later periods of the cumulations for gum and
patch.
Since I2 and H2 are related arithmetically by equation (5),
we would expect to see similarities in their graphical rep-
resentations. This is borne out in Figure 2 in which I2 and
H values are plotted across time for the cumulative meta-
analyses of the five interventions.BMC Medical Research Methodology 2004, 4:18 http://www.biomedcentral.com/1471-2288/4/18
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Note that I2 is limited by [0, 1] and trends that approach
these limits will be compressed. On the other hand, while
H has a lower limit of 1, it has no theoretical upper limit.
However, since very little heterogeneity is expected in
such high values, the scale is wasted, producing a com-
pression effect in the lower portion of the ordinate range.
This effect is much more pronounced than the trends seen
in the I2 curves, resulting in poorer resolution.
The evolution of measurable heterogeneity in relation to
time was considered previously. When plotted in this
manner, periods of increased or decreased heterogeneity
may be identified for further study. For instance, I2 was
about twice its final value in the mid-1980's for nicotine
replacement therapy using gum (Figure 3, column 1). Fol-
lowing this period, I2 values hovered around 20% until
2000. The increase in heterogeneity may be due to the dif-
ferences in the components of the intervention [17-20] or
quality of the research [20-22] in those studies that were
conducted at the time. For instance, one of the studies in
1983 [17] assigned participants into one of four groups,
only one of which included the intervention of interest
(nicotine gum). In the meta-analysis, the results for the
other three groups were collapsed to provide a "control"
group against which the effect of nicotine gum could be
compared.
By cumulatively performing a meta-analysis by ascending
(or descending) control event rates, additional informa-
tion may be gained in the assessment of heterogeneity
Cumulative meta-analytic estimates of the odds ratio (OR) for clonidine, nicotine replacement therapy (gum and patch), physi- cian advice and acupuncture as smoking cessation interventions across time are shown in the first row of graphs Figure 1
Cumulative meta-analytic estimates of the odds ratio (OR) for clonidine, nicotine replacement therapy (gum and patch), physi-
cian advice and acupuncture as smoking cessation interventions across time are shown in the first row of graphs. The second 
row outlines the development of Cochrane's Q. The last row describes the trends in I2. All analyses were cumulated by publi-
cation date.
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especially with regard to the severity of the condition in
the study population. Note that small control event rates
were associated with smaller values of I2  in nicotine
replacement therapy using gum (Figure 3, column 2). In
studies in which the control event rate of smoking cessa-
tion was at least 10%, the proportional contribution of
between-study variance to the total variance was about
20%.
Meta-analyses may be performed cumulatively over the
studies arranged in order of increasing sample size (Figure
3, column 3). The smaller number of endpoints associ-
ated with smaller studies impacts on their variability. In
the case of nicotine replacement therapy using gum, the
variability seemed to arise from within-study sources
rather than between-study sources. It was not until more
than 3,500 patients were studied cumulatively in 28
studies that appreciable heterogeneity as measured by I2
was detected.
Results for the meta-analyses performed according to year,
control event rate and sample size for patches, physician
advice and acupuncture are available in Additional File 1.
Discussion
We have provided a description of the use of cumulative
meta-analytic techniques to trace the evolution of meas-
ures of heterogeneity. By evaluating the patterns in heter-
ogeneity, temporal or other relationships may be
examined with the view of evaluating the impact of spe-
cific levels of heterogeneity in association with the overall
estimate of effect. For instance, the increase in
A comparison between trends in I2 (first row) and H (second row) across time for smoking cessation interventions Figure 2
A comparison between trends in I2 (first row) and H (second row) across time for smoking cessation interventions.
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heterogeneity measured using I2 showed an approximate
doubling over the early 1980's that may be due to differ-
ences in study quality or components of the intervention
[14].
The techniques described above will facilitate the exami-
nation of sources or relationships that contribute to heter-
ogeneity. The measured examination of such sources has
been advocated widely [8,23,24] and, prior to the intro-
duction of I2 and related measures, was limited to general
advice – differentiating between clinical and statistical
heterogeneity [23], covariate-specific evaluations [25], etc.
The use of the newly developed measures will allow the
more systematic examination of meta-analytic variation.
The discussion regarding the cumulative meta-analysis of
effect estimates (eg, OR, relative risks) has previously
focused on demonstrating that statistical significance
could have been reached at an earlier period or using a
smaller number of patients [3-5]. In contrast, the use of
cumulative meta-analysis in the examination of heteroge-
neity does not have as its primary objective the anticipa-
tion of any attainment of statistical significance in the
level of variability.
Our paper had several limitations. First, we relied on
available Cochrane reviews in calculating summary esti-
mates. We assumed that the authors of the systematic
reviews conducted a reasonable effort to identify,
Trends in the summary odds ratio (OR) and I2 for nicotine replacement therapy using gum Figure 3
Trends in the summary odds ratio (OR) and I2 for nicotine replacement therapy using gum. The first column shows trends by 
year of publication, the second by control event rate, and the last by cumulative sample size.
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appraise, extract, and analyse the individual trial reports
relating to the particular intervention. In 1998, Cochrane
reviews were found to be more methodologically rigorous
in comparison to paper-based meta-analysis [26] and we
have had no cause to have reservations about the general-
isation of this finding to the present time.
Second, we limited our analysis to interventions designed
to promote smoking cessation. The choice of topic may
very well have resulted in peculiar or distinctive results.
However, we were primarily interested in describing an
approach to assessing heterogeneity rather than concen-
trating on the effectiveness of the interventions.
Third, we limited our description of the relationship
between heterogeneity and specific covariates to three:
year, control event rate and sample size. We submit that
additional covariates may be used in similar ways to trace
the development of heterogeneity. Some useful covariates
may include study-related variables such as study quality,
patient-related variables such as age or severity of disease,
treatment-related variables such as duration or delay in
receipt of treatment, etc. As with meta-regression tech-
niques, the examination of these relationships depends
on the availability of the variables in the individual study
reports.
The evaluation of heterogeneity should be seen as crucial
to the overall approach used in systematic reviews. We
believe that the present focus on the meta-analytic sum-
maries of primary effect estimates without regard for the
sources of variability will lead to the production of an
incomplete picture of the intervention in question. The
development of measures of heterogeneity will certainly
improve the subsequent description and examination of
the phenomenon; I2 is already included in the standard
software used in the preparation of Cochrane reviews. In
the same way that we demand the reporting of measures
of variability with conventional measures of central ten-
dency (ie., standard deviation with the mean), should we
not also expect quantitative summaries to include I2 (or
similar measures)?
Conclusions
When combined with cumulative meta-analytic tech-
niques, measures of heterogeneity such as I2 and H allow
for the easy description of the impact of variability. This
adds an important perspective in describing the evolution
of pooled effect estimates.
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